# Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

> **NCT06124378** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **First Affiliated Hospital of Guangxi Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Colonic Neoplasms
- Neoadjuvant Therapy
- Immune Checkpoint Inhibitors

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **PROCEDURE:** Colectomy

## Key facts

- **NCT ID:** NCT06124378
- **Lead sponsor:** First Affiliated Hospital of Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-13
- **Primary completion:** 2025-02-28
- **Final completion:** 2026-11-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06124378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06124378, "Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06124378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*